Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial - PubMed
8 hours ago
- #Clinical Trial
- #Acoramidis
- #ATTR-CM
- Acoramidis, a therapy that stabilizes serum transthyretin (sTTR), showed sustained clinical benefits through month 54 in an open-label extension of the ATTRibute-CM trial for transthyretin amyloid cardiomyopathy (ATTR-CM).
- Continuous acoramidis treatment significantly reduced risks of all-cause mortality (HR 0.55), cardiovascular-related mortality (HR 0.51), and first cardiovascular hospitalization (HR 0.53) through month 54.
- Biomarkers of disease progression, including NT-proBNP levels, were stabilized with continuous treatment, and functional capacity (6MWD) and heart failure health status (KCCQ-OS score) were maintained.
- Participants who switched from placebo to acoramidis at month 30 also showed stabilization in NT-proBNP and KCCQ-OS scores, with improvements in sTTR levels and 6MWD through month 54.
- No new long-term safety concerns were identified, supporting the importance of early and continuous acoramidis treatment for ATTR-CM patients.